Henry Schein Inc (NASDAQ:HSIC) posts Q2 FY23 sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2% decrease in local currencies excluding acquisitions, 2.9% growth from acquisitions, and a 0.4% decrease related to foreign currency exchange.
Sales of PPE products and COVID-19 test kits were $163 million, a decrease of $96 million versus the prior-year period, excluding sales of PPE products and COVID-19 test kits, Q2 internal sales growth in local currencies was 3.3% compared with the prior-year period.
Global Dental sales were $2.0 billion, an increase of 5.6% Y/Y. Global Medical sales were $1.0 billion, down 4.6% Y/Y.
Adjusted EPS of $1.31, up 0.8%, beat the estimate of $1.25.
Guidance: Henry Schein reaffirms the FY23 adjusted EPS outlook of $5.18-$5.35, compared to the consensus of $5.27.
The company expects year-over-year growth in diluted EPS to be higher in the fourth quarter than in the third quarter.
2023 sales growth is expected to be approximately 1% to 3% over 2022, unchanged from prior guidance.
Price Action: HSIC stock is down 3.19% at $75.60 on the last check Monday.
Photo via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
